Michael McNulty

The board meeting agenda focuses on the review of several pharmaceutical-related items, including revisions to prior authorization criteria for various medication categories such as immune globulins, oncology agents, epidermolysis bullosa treatments, and high-cost dosage forms. The meeting also involves establishing new prior authorization criteria for agents addressing cholestatic pruritus, chronic hand eczema, hereditary angioedema, macular telangiectasia, non-factor hemophilia prophylaxis, and Prader-Willi syndrome. Additionally, the agenda includes discussions on safe usage guidelines for ADHD and antipsychotic medications, as well as utilization data for T-cell receptor immunotherapy agents.

The meeting agenda focuses on reviewing pharmaceutical criteria and utilization data. Key topics include proposed changes to prior authorization criteria for various drug categories, including oncology agents, Duchenne Muscular Dystrophy gene therapy, generalized Myasthenia Gravis agents, and metabolic dysfunction-associated steatohepatitis treatments. Additionally, the board will discuss new criteria for Hemophilia prophylaxis and Prader-Willi Syndrome agents, as well as review utilization data for T-cell receptor immunotherapy. Tentative agenda items from previous MHMAC and PDL meetings concerning ADHD, antidepressants, and postpartum depression medications are also slated for review.

The committee discussed safety and clinical practice impacts for ADHD and antidepressant medications, resulting in the approval of new safety edits and updated step-therapy requirements. For postpartum depression agents, the committee recommended removing step therapy requirements for Zurzuvae and clarifying clinical assessment timelines. Additionally, the committee engaged in discussions regarding management strategies for antipsychotic medications and approved a proposal to reschedule the committee's quarterly meeting cycle.

The committee meeting agenda covers the review of new drug placements on the Preferred Drug List, including various medications for pain management, hypertension, and diabetes. New business includes discussions and committee recommendations for new Preferred Drug List classes, such as agents for Familial Chylomicronemia Syndrome, Non-Factor Hemophilia A and B Prophylaxis, and Sickle Cell Anemia treatments. Additionally, the agenda addresses new drugs to be added to existing classes for conditions like Dry Eye Disease, Atopic Dermatitis, Migraine treatments, Thrombopoiesis Stimulating Proteins, and nonhormonal therapies for Vasomotor Symptoms, with opportunities for public comment for each item.

The committee held a session to review and approve several new drug placements, including various biosimilar products and topical formulations. New PDL classes were established for non-opioid treatments for acute pain and denosumab products for oncology and osteoporosis. Additionally, several new drugs were added to existing PDL classes, such as colony stimulating factor products, oral corticosteroids, DPP-4 inhibitors, immunomodulation agents for Crohn's disease, rapid-acting insulin biosimilars, phosphate binder agents, and pulmonary arterial hypertension agents. The committee also discussed the strategic implementation of including non-drug items on the preferred drug list to potentially enhance pricing negotiations.